mProX™ Human PDCD1 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;H9C2

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Immunology Research

Related Diseases

Systemic Lupus Erythematosus 2; Multiple Sclerosis

Gene ID

Human:5133

UniProt ID

Human:Q15116

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PDCD1, also known as PD-1, is a gene that plays a role in the immune response and has applications in various types of cancer. In gastric cancer, a study found that high expression of PDCD1 was associated with a less favorable outcome, and the gene was positively linked to the expression of immune checkpoints. In hepatocellular carcinoma, overexpression of PDCD1 was associated with cancer progression and immune cell infiltration. In endometrial cancer, PDCD1 was identified as part of an inflammatory response-related signature that had prognostic value and could enhance targeted therapy. Additionally, in CAR T cell therapy, deleting the CTLA4 gene, which is related to PDCD1, was found to enhance the function of CAR T cells. Overall, PDCD1 has implications for understanding the tumor immune microenvironment, predicting patient outcomes, and improving immunotherapeutic strategies in various cancers.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PDCD1 Stable Cell Line (S01YF-1023-PY165). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

How does PDCD1 polymorphism influence the efficacy of immunotherapy? May 31 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

PDCD1 polymorphisms, like PD-1.6, can be associated with the occurrence of severe immune-related adverse events in patients treated with immunotherapy, indicating its potential role in predicting treatment response. May 31 2022

chat Casey Brown (Verified Customer)

Can altering PDCD1 expression patterns overcome T cell exhaustion? Oct 14 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Using CRISPR/Cas9 exon skipping strategy to modify PD-1 expression patterns in T cells could help overcome T cell exhaustion, a potential approach for adoptive cell immunotherapies. Oct 14 2021

Published Data

Fig.1 The influence of Pdcd1 depletion on apoptosis induction by DOX in H9c2 cells is being investigated.

The assessment of apoptosis involved a luciferase assay employing annexin V, a marker specific to apoptosis. The level of apoptosis induced by DOX treatment was quantified as a percentage relative to untreated control cells. The examination of apoptosis in Pdcd1 knockdown cells was carried out following exposure to DOX (1 µM) for different durations (1-12 hours). It's important to note that the mock group represented in the graph should not be confused with the independent group under investigation.

Ref: Kanno, Syu-Ichi, and Akiyoshi Hara. "The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin‑induced cardiotoxicity." Molecular Medicine Reports 23.2 (2021): 1-1.

Pubmed: 33300057

DOI: 10.3892/mmr.2020.11752

Research Highlights

Xiang, Qian-Ming. et al. "Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study." BMC cancer, 2023.
The expression of SH2 domain containing 1A (SH2D1A) has been associated with the progression of cancer. However, the specific role of SH2D1A in hepatocellular carcinoma (HCC) has yet to be documented.
Xiang, Qian-Ming. et al. "Overexpression of SH2D1A promotes cancer progression and is associated with immune cell infiltration in hepatocellular carcinoma via bioinformatics and in vitro study." BMC cancer, 2023.
Pubmed: 37858067 DOI: 10.1186/s12885-023-11315-1

Heimli, Marte. et al. "Human thymic putative CD8Œ±Œ± precursors exhibit a biased TCR repertoire in single cell AIRR-seq." Scientific reports, 2023.
The development of T cells in the thymus involves two key processes: the rearrangement of the T cell receptor (TCR) and the determination of the TCR's ability to bind to self-peptide-MHC complexes presented by antigen-presenting cells. Depending on this avidity for self, T cells may undergo negative selection or differentiate into unconventional lineages like regulatory T cells and CD8[Formula: see text] T cells. A study was conducted using single cell adaptive immune receptor repertoire sequencing (scAIRR-seq) to examine the impact of the adaptive immune receptor repertoire on thymocyte development. Thymocytes from young pediatric thymi and blood were analyzed, along with the expression of PDCD1.
Heimli, Marte. et al. "Human thymic putative CD8Œ±Œ± precursors exhibit a biased TCR repertoire in single cell AIRR-seq." Scientific reports, 2023.
Pubmed: 37853083 DOI: 10.1038/s41598-023-44693-4